In the News

Guideline offers recommendations on anticoagulation, thromboses in vascular liver disorders

Among other guidance, the American College of Gastroenterology recommends anticoagulation for all patients without cirrhosis who have acute symptomatic portal vein thrombosis or mesenteric vein thrombosis in the absence of any contraindication.

More concentrated care linked to adverse outcomes in patients with cirrhosis

A retrospective cohort study looked at patients with cirrhosis who were enrolled in Medicare and had had more than four outpatient visits over 180 days.

C. diff colonization more common in patients living near livestock

Testing for Clostridioides difficile at one Wisconsin hospital found higher risk for colonization among hematology-oncology patients but an association of residential proximity to livestock farms and colonization only among patients admitted to other units.

MKSAP Quiz: Evaluation for incidental gallbladder findings

A 65-year-old man is evaluated after a screening ultrasound for abdominal aortic aneurysm showed a gallbladder polyp and numerous gallstones. He reports no symptoms. Which is the most appropriate next step in management?

Spotlight on ulcerative colitis

In the past month, the American Gastroenterological Association published new recommendations, a meta-analysis compared first- and second-line treatments, and a study found a recent decrease in colorectal cancer incidence in patients with ulcerative colitis.

FDA recommends transition to duodenoscopes with innovative designs

To date, the FDA has cleared three duodenoscopes with newer design features that can facilitate cleaning, reduce contamination, and reduce disease transmission following reprocessing.

Histamine-2 receptor antagonists recalled due to detection of probable carcinogen

Batches of ranitidine and nizatidine have been recalled in the past month due to the potential presence of N-nitrosodimethylamine.

First targeted therapy approved to treat patients with GI stromal tumors, rare mutation

A kinase inhibitor was approved to treat adults with an unresectable or metastatic gastrointestinal (GI) stromal tumor who harbor a platelet-derived growth factor receptor alpha exon 18 mutation.

GI bleeding prophylaxis recommended in high-risk critically ill patients

Proton-pump inhibitors appeared to reduce bleeding risk more than histamine-2 receptor antagonists.